These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 19222409

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
    Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, Savarino V, Sturniolo GC, Vecchi M, Ardia A, Bellinvia S.
    Aliment Pharmacol Ther; 2009 Nov 01; 30(9):908-18. PubMed ID: 19678813
    [Abstract] [Full Text] [Related]

  • 5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA.
    Dan Med Bull; 2000 Feb 01; 47(1):20-41. PubMed ID: 10709142
    [Abstract] [Full Text] [Related]

  • 6. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S.
    Gastroenterology; 2010 Apr 01; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 01; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 10. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ.
    J Clin Gastroenterol; 2008 Apr 01; 42(4):338-44. PubMed ID: 18277908
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ, Hanauer SB, Buch A.
    Aliment Pharmacol Ther; 2004 May 15; 19(10):1089-98. PubMed ID: 15142198
    [Abstract] [Full Text] [Related]

  • 15. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K, Becker K, Ueberschaer B.
    Z Gastroenterol; 1996 Apr 15; 34(4):225-9. PubMed ID: 8686349
    [Abstract] [Full Text] [Related]

  • 16. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K, Trenk D, Rössle M, Cap M, Zähringer A, Wacheck V, Remmler C, Cascorbi I, Kreisel W, Novacek G.
    Eur J Clin Invest; 2007 Jul 15; 37(7):558-65. PubMed ID: 17576207
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.